SG11202101785UA - Process for preparing jak inhibitors and intermediates thereof - Google Patents

Process for preparing jak inhibitors and intermediates thereof

Info

Publication number
SG11202101785UA
SG11202101785UA SG11202101785UA SG11202101785UA SG11202101785UA SG 11202101785U A SG11202101785U A SG 11202101785UA SG 11202101785U A SG11202101785U A SG 11202101785UA SG 11202101785U A SG11202101785U A SG 11202101785UA SG 11202101785U A SG11202101785U A SG 11202101785UA
Authority
SG
Singapore
Prior art keywords
intermediates
jak inhibitors
preparing jak
preparing
inhibitors
Prior art date
Application number
SG11202101785UA
Inventor
Pierre-Jean Colson
Gene Timothy Fass
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of SG11202101785UA publication Critical patent/SG11202101785UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
SG11202101785UA 2018-09-04 2019-09-03 Process for preparing jak inhibitors and intermediates thereof SG11202101785UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862726600P 2018-09-04 2018-09-04
PCT/US2019/049338 WO2020051135A1 (en) 2018-09-04 2019-09-03 Process for preparing jak inhibitors and intermediates thereof

Publications (1)

Publication Number Publication Date
SG11202101785UA true SG11202101785UA (en) 2021-03-30

Family

ID=67957449

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202101785UA SG11202101785UA (en) 2018-09-04 2019-09-03 Process for preparing jak inhibitors and intermediates thereof

Country Status (15)

Country Link
US (1) US10844057B2 (en)
EP (1) EP3837253B1 (en)
JP (1) JP2021535176A (en)
KR (1) KR20210056382A (en)
CN (1) CN112638902A (en)
AR (1) AR116116A1 (en)
AU (1) AU2019335199A1 (en)
BR (1) BR112021004087A2 (en)
CA (1) CA3108848A1 (en)
IL (1) IL281152B2 (en)
MX (1) MX2021002273A (en)
PH (1) PH12021550388A1 (en)
SG (1) SG11202101785UA (en)
TW (1) TWI808250B (en)
WO (1) WO2020051135A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3371186A1 (en) 2015-11-03 2018-09-12 Theravance Biopharma R&D IP, LLC Jak kinase inhibitor compounds for treatment of respiratory disease
EP3592742B1 (en) 2017-03-09 2021-05-19 Theravance Biopharma R&D IP, LLC Jak inhibitors containing a 4-membered heterocyclic amide
ES2955717T3 (en) 2018-09-04 2023-12-05 Theravance Biopharma R&D Ip Llc 5- to 7-membered heterocyclic amides as JAK inhibitors
LT3837258T (en) 2018-09-04 2024-05-27 Theravance Biopharma R&D Ip, Llc Dimethyl amino azetidine amides as jak inhibitors
TW202144343A (en) 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Crystalline hydrate of a jak inhibitor compound
WO2021226637A1 (en) * 2020-05-08 2021-11-11 Theravance Biopharma R&D Ip, Llc Method of treating a patient infected with a coronavirus with nezulcitinib
WO2022081872A1 (en) * 2020-10-16 2022-04-21 Gb008, Inc. Janus kinase inhibitors
WO2022271604A1 (en) 2021-06-21 2022-12-29 Theravance Biopharma R&D Ip, Llc Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l
WO2023215478A1 (en) 2022-05-05 2023-11-09 Theravance Biopharma R&D Ip, Llc Nezulcitinib for delivery by nebulized oral inhalation
WO2023230236A1 (en) * 2022-05-26 2023-11-30 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812462A (en) * 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
AU2004259012C1 (en) 2003-07-23 2012-08-02 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (en) 2008-11-06 2010-05-20 Shionogi & Co Ltd Indazole derivative having ttk inhibitory action
JOP20190231A1 (en) * 2009-01-15 2017-06-16 Incyte Corp Processes for preparing jak inhibitors and related intermediate compounds
WO2010114971A1 (en) 2009-04-03 2010-10-07 Sepracor Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
CN102595899A (en) * 2009-08-10 2012-07-18 埃皮瑟瑞克斯有限公司 Indazoles as WNT/B-catenin signaling pathway inhibitors and therapeutic uses thereof
BR112012018413A2 (en) 2009-12-21 2016-08-09 Samumed Llc 1h-pyrazol [3,4-b] pyridines and therapeutic uses thereof.
US8575336B2 (en) * 2011-07-27 2013-11-05 Pfizer Limited Indazoles
UA111854C2 (en) * 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
AU2014225938B2 (en) * 2013-03-06 2018-07-19 Incyte Holdings Corporation Processes and intermediates for making a JAK inhibitor
MD4649C1 (en) 2013-12-05 2020-04-30 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
EP3143021B1 (en) 2014-05-14 2019-06-12 Pfizer Inc Pyrazolopyridines and pyrazolopyrimidines
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (en) 2015-03-30 2016-10-06 주식회사 녹십자 Tnik ikk tbk1 pyrazole derivatives as tnik ikk and tbk1 inhibitor and pharmaceutical composition comprising same
EP3371186A1 (en) * 2015-11-03 2018-09-12 Theravance Biopharma R&D IP, LLC Jak kinase inhibitor compounds for treatment of respiratory disease
EP3865481A1 (en) * 2015-11-03 2021-08-18 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
EP3371185B1 (en) 2015-11-03 2020-09-30 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
EP3592742B1 (en) 2017-03-09 2021-05-19 Theravance Biopharma R&D IP, LLC Jak inhibitors containing a 4-membered heterocyclic amide
CA3059790A1 (en) 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Crystalline forms of a jak inhibitor compound
KR102568333B1 (en) 2017-05-01 2023-08-18 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Methods of Treatment Using JAK Inhibitor Compounds
AR111495A1 (en) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc FUSIONED IMIDAZO-PIPERIDINE COMPOUNDS AS JAK INHIBITORS
LT3837258T (en) 2018-09-04 2024-05-27 Theravance Biopharma R&D Ip, Llc Dimethyl amino azetidine amides as jak inhibitors
ES2955717T3 (en) 2018-09-04 2023-12-05 Theravance Biopharma R&D Ip Llc 5- to 7-membered heterocyclic amides as JAK inhibitors
MX2021004582A (en) 2018-10-29 2021-06-15 Theravance Biopharma R&D Ip Llc 2-azabicyclo hexane compound as jak inhibitor.
JP2022523274A (en) 2019-02-25 2022-04-21 ホーナン メディノ ファーマシューティカル テクノロジー カンパニー リミテッド JAK inhibitor compounds and their use

Also Published As

Publication number Publication date
WO2020051135A1 (en) 2020-03-12
IL281152B2 (en) 2023-12-01
US10844057B2 (en) 2020-11-24
PH12021550388A1 (en) 2021-11-08
MX2021002273A (en) 2021-05-27
AU2019335199A1 (en) 2021-03-11
CA3108848A1 (en) 2020-03-12
IL281152B1 (en) 2023-08-01
IL281152A (en) 2021-04-29
EP3837253B1 (en) 2023-06-07
BR112021004087A2 (en) 2021-05-25
KR20210056382A (en) 2021-05-18
EP3837253C0 (en) 2023-06-07
TW202024074A (en) 2020-07-01
EP3837253A1 (en) 2021-06-23
AR116116A1 (en) 2021-03-31
JP2021535176A (en) 2021-12-16
TWI808250B (en) 2023-07-11
US20200071324A1 (en) 2020-03-05
CN112638902A (en) 2021-04-09

Similar Documents

Publication Publication Date Title
IL281152A (en) Process for preparing jak inhibitors and intermediates thereof
IL292648A (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
EP3645529A4 (en) Process for preparing lifitegrast and intermediates thereof
HK1254367A1 (en) New process and intermediates
EP3376870A4 (en) Process for the preparation of kinase inhibitors and intermediates thereof
ZA202006128B (en) Method for preparing pyrroloaminopyridazinone compound and intermediates thereof
ZA202101214B (en) Process and intermediates for the preparation of bilastine
IL287876A (en) Jak inhibitors
ZA202003590B (en) Process for the preparation of opicapone and intermediates thereof
ZA201807240B (en) Method for preparing azoxystrobin intermediates
IL283901A (en) Pharmaceutical process and intermediates
EP3262025A4 (en) Novel intermediates for preparing dpp-iv inhibitors, preparing method thereof and preparing method of dpp-iv inhibitors using the same
GB201416678D0 (en) Process For Synthesizing Ergothioneine And Its Intermediates
IL266761B (en) Chemical process for preparing imidazopyrrolidinone derivatives and intermediates thereof
EP3368537A4 (en) Process for preparing ibrutinib and its intermediates
PL3737685T3 (en) Process for the preparation of crisaborole and its intermediates
GB201820751D0 (en) Methods for preparing intermediates
IL290381A (en) Jak inhibitors
IL253077A0 (en) Process and intermediates for the preparation of perampanel
ZA202107053B (en) Novel process for the preparation of filgotinib and intermediates thereof
IL272837A (en) Process for the preparation of tubulysins and intermediates thereof
IL291611A (en) Jak inhibitors
PT3969459T (en) Process and intermediates for the preparation of eldecalcitol
PT3915989T (en) Jak inhibitor and preparation method therefor
EP3679008A4 (en) An improved process for preparation of trifluoromethylbenzaldehydes and intermediates thereof